SPECT/CT

Radiopharmaceuticals Market Size (2022-2030) Share, Industry Trends, Growth, Challenges, and Forecast: Growth Plus Reports

Retrieved on: 
Jeudi, octobre 6, 2022
Adoption, Radiopharmaceutical, CDC, Cardiovascular disease, Therapy, Prevalence, Growth, Diagnosis, SPECT/CT, CAGR, Neoplasm, Centers for Disease Control and Prevention timeline, Lists of diseases, World Nuclear Association, Cancer, Center, Impact, US, Awareness, Conditional sentence, CVD, PET/CT, Immunotherapy, Death, COVID-19, Disease Control Priorities Project, 11C, Medical imaging, Medical device, Pharmaceutical industry, Speciality chemicals, Others

The increased utilization of cutting-edge technology has made it possible to use radiopharmaceuticals more effectively for disease diagnosis and therapy.

Key Points: 
  • The increased utilization of cutting-edge technology has made it possible to use radiopharmaceuticals more effectively for disease diagnosis and therapy.
  • The global radiopharmaceuticals market has been analyzed from four perspectives type, application, end user, and region.
  • Based on type, the global radiopharmaceuticals market is classified into:
    With the largest market share in 2021, the diagnostic radiopharmaceuticals segment dominates the global radiopharmaceutical market.
  • Speak to our Analyst to Understand the Impact of COVID-19 on Your Business: https://growthplusreports.com/inquiry/speak-analyst/radiopharmaceuticals...
    Based on application, the global radiopharmaceuticals market is segmented into:
    In terms of market share, the oncology segment will dominate the radiopharmaceuticals market in 2021.

Radiopharmaceuticals Market Size (2022-2030) Share, Industry Trends, Growth, Challenges, and Forecast: Growth Plus Reports

Retrieved on: 
Jeudi, octobre 6, 2022
Adoption, Radiopharmaceutical, CDC, Cardiovascular disease, Therapy, Prevalence, Growth, Diagnosis, SPECT/CT, CAGR, Neoplasm, Centers for Disease Control and Prevention timeline, Lists of diseases, World Nuclear Association, Cancer, Center, Impact, US, Awareness, Conditional sentence, CVD, PET/CT, Immunotherapy, Death, COVID-19, Disease Control Priorities Project, 11C, Medical imaging, Medical device, Pharmaceutical industry, Speciality chemicals, Others

The increased utilization of cutting-edge technology has made it possible to use radiopharmaceuticals more effectively for disease diagnosis and therapy.

Key Points: 
  • The increased utilization of cutting-edge technology has made it possible to use radiopharmaceuticals more effectively for disease diagnosis and therapy.
  • The global radiopharmaceuticals market has been analyzed from four perspectives type, application, end user, and region.
  • Based on type, the global radiopharmaceuticals market is classified into:
    With the largest market share in 2021, the diagnostic radiopharmaceuticals segment dominates the global radiopharmaceutical market.
  • Speak to our Analyst to Understand the Impact of COVID-19 on Your Business: https://growthplusreports.com/inquiry/speak-analyst/radiopharmaceuticals...
    Based on application, the global radiopharmaceuticals market is segmented into:
    In terms of market share, the oncology segment will dominate the radiopharmaceuticals market in 2021.

World Nuclear Imaging Agents Market Report 2022: Regulatory and Reimbursements, Procedures, & Forecasts 2015-2030 Featuring Cardinal Health, GE Healthcare, Novartis, Bracco Imaging, DuPont de Nemours - ResearchAndMarkets.com

Retrieved on: 
Mardi, septembre 20, 2022
Health, Other Health, Photon, Single-photon emission computed tomography, COVID-19, Epidemiology, Country, PET/MRI, Diagnosis, Nuclear, PET/CT, ASP, Review, CMO, Industry, Strategic planning, Segment, Volume, Investment, PET, GlobalData, Region, Medical imaging, SPECT, SWOT, Cancer, Positron emission tomography, SPECT/CT, SWOT analysis, Renewable energy, Retail, Public relations, Forecast

The model discusses in detail the impact of COVID-19 on Nuclear Imaging Agents market for the year 2020 and beyond.

Key Points: 
  • The model discusses in detail the impact of COVID-19 on Nuclear Imaging Agents market for the year 2020 and beyond.
  • Nuclear Imaging is a noninvasive medical technique which uses radioactive tracers (generally F-18 Fluorodeoxyglucose) to assess and diagnose bodily functions and diseases.
  • Nuclear Imaging Agent's have been classified into Positron Emission Tomography (PET) Systems and Single Photon Emission Computed Tomography (SPECT) Systems.
  • Track device sales in the global and country-specific Nuclear Imaging Agents market from 2015-2030.

Attralus Announces Presentation of Clinical Data for AT-01 (Iodine (I-124) Evuzamitide), a Novel Amyloid-Specific Imaging Agent, at the 18th International Symposium on Amyloidosis

Retrieved on: 
Jeudi, septembre 8, 2022
Whole body imaging, University, Columbia University, Spleen, Cardiac amyloidosis, College of Physicians and Surgeons, Physician, Liver, SAN, SPECT/CT, ATTR, ISA, N-terminal prohormone of brain natriuretic peptide, Kidney, Program, Heart, AL, Serum, Pathology, Diagnosis, Arnold, GLOBE, PAR, PET/CT, Iodine, Surgeon, International Symposium on Endovascular Therapy, Patient, Medical imaging, Amyloidosis, Cardiology, Medicine, MD

These data were included in oral and poster presentations at the 18th International Symposium on Amyloidosis (ISA) taking place September 4-8, 2022, in Heidelberg, Germany.

Key Points: 
  • These data were included in oral and poster presentations at the 18th International Symposium on Amyloidosis (ISA) taking place September 4-8, 2022, in Heidelberg, Germany.
  • Today the diagnosis of amyloidosis is a long, complex process, and many patients with systemic amyloidosis remain undiagnosed.
  • AT-01 is a pattern recognition peptide that binds electronegative motifs, fibrils, and highly sulfated heparan sulfate glycosaminoglycans in amyloid deposits.
  • Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis.

Global Nuclear Medicine Market Report 2022: Growing Popularity of Personalized Treatment Fueling Sector - ResearchAndMarkets.com

Retrieved on: 
Mercredi, septembre 7, 2022
Biotechnology, Pharmaceutical, Health, Curium, Health care, Conditional sentence, Breast, PET, PET-CT, Cancer, Ageing, Gene, Government, SPECT/CT, Death, WHO, Disease, Colon, SPECT, Precision medicine, Person, Lists of countries and territories, Infection, Rectum, Diagnosis, Somatostatin, Radiopharmaceutical, Lung, Nuclear medicine, Neurology, Psychiatry, Society of Nuclear Medicine and Molecular Imaging, CAGR, Population, Adult, Prostate, Copper (64Cu) oxodotreotide, Elective surgery, NETS, Gastroenterology, Genomics, Cardiology, Environment, Patient, Medical imaging

The Global Nuclear Medicine Market is expected to grow at a CAGR of 9.32% and reach USD8804.54 million through 2027.

Key Points: 
  • The Global Nuclear Medicine Market is expected to grow at a CAGR of 9.32% and reach USD8804.54 million through 2027.
  • The growing popularity of targeted radionuclide therapy provides efficacious treatment modalities against cancer.
  • The growing popularity of personalized treatment has significantly increased the demand for nuclear medicine.
  • Thus, the technological advancements
    In this report, the Global Nuclear Medicine Market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

New ASNC-led Guideline Details How to Use CT in Hybrid Nuclear-CT Cardiac Imaging

Retrieved on: 
Mardi, septembre 6, 2022
American Association of Physicists in Medicine, Inflammation, PET, Guideline, ASNC, American Association, Master of Science, SPECT/CT, OnDemand, Cross, Solution, Houston Methodist Hospital, Society, Table, Molecular imaging, Physician, Journal of Nuclear Cardiology, MPI, CACS, Society of Cardiovascular Computed Tomography, Organization, Journal, Physicist, Health, American Society of Nuclear Cardiology, Collaboration, Atherosclerosis, SCCT, PET/CT, Competence, Hibernation, Knowledge, AAPM, Coronary artery disease, Hardware, Society of Nuclear Medicine and Molecular Imaging, Cardiology, Patient, SNMMI, Medical imaging, Medicine, Software, MD

FAIRFAX, Va., September 06, 2022 /PRNewswire-PRWeb/ -- The American Society of Nuclear Cardiology (ASNC) and three partner societies have come together to answer cardiac imagers' questions about SPECT/CT and PET/CT imaging with attenuation correction, localization of radiotracer uptake and coronary artery calcium scoring (CACS). In a new multisociety guideline published today in the Journal of Nuclear Cardiology, the organizations recommend training and competency requirements for imaging physicians and technologists; describe models for collaborative, cross-specialty study interpretation and reporting; and suggest solutions for the preauthorization and reimbursement challenges that some labs have faced with hybrid imaging in nuclear cardiology.

Key Points: 
  • "Assessing atherosclerosis burden in hybrid imaging improves the diagnostic accuracy of MPI studies and help clinicians identify high-risk patients and treat them accordingly.
  • The question is not whether today's cardiac imaging labs should adopt hybrid imaging but rather how to adapt their labs for the routine use of SPECT/CT and PET/CT.
  • Imaging teams will find the new guideline is a blueprint for modernizing their labs for the delivery of hybrid nuclear-CT imaging.
  • ASNC's Hybrid Imaging Symposium will be delivered in two parts:
    Part 1 is currently available OnDemand on the ASNC2022 online meeting platform.

Lantheus Highlights Preliminary Study Results Demonstrating Potential of NM-01, a Novel Technetium-99m SPECT/CT Imaging Agent, to Assess PD-L1 Expression for Immunotherapy in Cancer

Retrieved on: 
Lundi, juin 13, 2022
LNTH, Immunotherapy, Large-cell lung carcinoma, Immunohistochemistry, Company, Securities Exchange Act of 1934, Neoplasm, National Food Security Act, 2013, Melanoma, Private Securities Litigation Reform Act, Forward-looking statement, Security (finance), Society, Ventana, Metastasis, U.S. Securities and Exchange Commission, Pecan, Female, Intelligence, Method, Male, Risk, Patient, GLOBE, IHC, PD-1, SPECT/CT, NM-01, Wilms' tumor, NASDAQ, Securities Act of 1933, Molecular imaging, Interim, PD-L1, Medical imaging, Cancer, MD, NSCLC

Lantheus presented preliminary results of the PD-L1 Expression in Cancer (PECan) study at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting.

Key Points: 
  • Lantheus presented preliminary results of the PD-L1 Expression in Cancer (PECan) study at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting.
  • In the preliminary analysis, investigators were able to evidence intertumoral heterogeneity of PD-L1 expression between primary tumors and metastases.
  • Further, baseline NM-01 SPECT/CT imaging was able to predict early metabolic 18F-FDG PET/CT response to anti-PD-L1 therapy in primary and metastatic tumors.
  • Following therapy, PD-L1 expression measured by NM-01 SPECT/CT imaging demonstrated stability or a reduction in the majority of responding lesions.

Global Molecular Imaging Equipment Growth Opportunities: Development of Novel Radiopharmaceuticals and Technical Advancements in AI and Hybrid Systems Fuel the Growth Pipeline - ResearchAndMarkets.com

Retrieved on: 
Lundi, mars 21, 2022
Pharmaceutical, Health, Other Health, Medical Devices, SPECT, SPECT/CT, Melanoma, Diagnosis, Research, Prostate cancer, Radio, Cancer, PET/CT, Alzheimer's disease, PET/MRI, Technology, MI, COVID-19, Radionuclide, Patient, Radiation, Medical imaging

The "Global Molecular Imaging (MI) Equipment Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Molecular Imaging (MI) Equipment Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • This research study presents an analysis of and growth opportunities for the global molecular imaging (MI) equipment market.
  • In 2020, the MI equipment market experienced a decline at the global level due to the supply challenges caused by the COVID-19 pandemic.
  • Development of novel radioisotopes is expected to increase the use of MI equipment for new clinical applications including Alzheimer's, melanomas, and prostate cancers.

POINT Biopharma Announces Abstract Publication of Dosimetry Data Findings from the Lead-In Cohort of the SPLASH trial in mCRPC at the 2022 SNMMI Mid-Winter & ACNM Annual Meeting

Retrieved on: 
Vendredi, février 25, 2022
GLOBE, Risk, SPLASH, Biopharma LLC, Prostate cancer, RPF, Exocrine gland, Abstract, Pharmacokinetics, PSMA, NASDAQ, MCRPC, COVID-19, Company, Private Securities Litigation Reform Act, Terminology, SNMMI, Intention, ORR, SPECT/CT, Cancer, Patient, Forward-looking statement, CEO, SEC, Actinium-225, Pharmaceutical industry, Medical imaging

INDIANAPOLIS, Feb. 25, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, announced today the publication of data from the 27-patient safety and dosimetry lead-in cohort for the Company’s Phase 3 SPLASH trial (NCT04647526) evaluating PNT2002 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) at the 2022 SNMMI Mid-Winter & ACNM Annual Meeting, taking place February 25-27, 2022.

Key Points: 
  • Data from the abstract titled Dosimetry Results from the SPLASH Trial (Abstract #: MWMA2244) demonstrated the following:
    For a cumulative administered activity of 27.2 GBq, i.e.
  • Organs receiving the largest absorbed doses were the lacrimal glands at 1.2 Gy/GBq, followed by the kidneys at 0.73 Gy/GBq.
  • The treatment regimen for the lead-in cohort is the same as being investigated in the randomization part of the trial.
  • Information about POINT Biopharma Global Inc.s Phase 3 SPLASH trial for metastatic castrate resistant prostate cancer (mCRPC) patients can be found at https://www.splashtrial.com/ .

Global Optical Preclinical Imaging Market (2021 to 2030) - by Modality, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Mardi, février 15, 2022
Health, Optical, Region, Yokohama, Magnetic resonance imaging, PET, Time, Visual acuity, X-ray, Infection, Human, Medical optical imaging, Kawasaki Medical School, MRI, Animal, SPECT/CT, Environment, Therapy, SPECT, Cardiology, Neoplasm, Neurology, Modality, Medicine, Optical flow, CT, Fluorescence, Molecular imaging, Research, Drug discovery, Probability, CAGR, Drug development, Medical imaging

The "Optical Preclinical Imaging Market by Modality and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Optical Preclinical Imaging Market by Modality and End User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
  • Optical preclinical imaging is the visualization of living animals for research purposes, such as drug discovery and development.
  • Preclinical imaging encompasses a range of modalities, and can be broadly classified as predominantly morphological/anatomical imaging approaches or molecular imaging techniques.
  • The global optical preclinical imaging market is segmented into modality, end user, and region.